83 results found.

Dementia, or Alzheimer's Disease Clinical Trial using [18F]NAV4694

Navidea Biopharmaceuticals - Recruiting 21 years or older.
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology.
[18F]NAV4694

Alzheimer's Disease Clinical Trial using Simvastatin + L-Arginine + Tetrahydrobiopterin

University of Massachusetts, Worcester - Recruiting 55 years to 85 years.
- Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease..
Simvastatin + L-Arginine + Tetrahydrobiopterin

Mild Cognitive Impairment Clinical Trial using [18F]NAV4694

Navidea Biopharmaceuticals - Recruiting 55 years or older.
- Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI).
[18F]NAV4694

Alzheimer's Disease Clinical Trial using florbetapir F 18

Avid Radiopharmaceuticals - Recruiting N/A or older.
- Evaluation of Reader Training Processes by Comparing Clinical Interpretations to Centralized Expert Reads.
florbetapir F 18

Alzheimer Disease Clinical Trial using crenezumab

Genentech - Recruiting 50 years or older.
- A Multicenter, Open-Label, Long-Term Safety Extension Of Phase II Studies ABE4869g And ABE4955g In Patients With Mild To Moderate Alzheimer's Disease.
crenezumab

Alzheimer Disease Clinical Trial using crenezumab; placebo

Genentech - Recruiting 30 years to 60 years.
- A DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY IN PRECLINICAL PSEN1 E280A MUTATION CARRIERS RANDOMIZED TO CRENEZUMAB OR PLACEBO, AND IN NONRANDOMIZED, PLACEBO-TREATED NONCARRIERS FROM THE SAME KINDRED, TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN THE TREATMENT OF AUTOSOMAL-DOMINANT ALZHEIMER'S DISEASE.
crenezumab; placebo

Alzheimer Disease Clinical Trial

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 70 years or older.
- Evaluating the Performance of Isotopic Brain Imaging of Glucose Metabolism Via PET (18F-FDG) and Perfusion SPECT (99mTc-ECD) for the Diagnosis of Prodromal Stage Alzheimer's Disease.

Alzheimer's Disease Clinical Trial using ITI-007; Placebo

Intra-Cellular Therapies, Inc. - Recruiting 65 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia..
ITI-007; Placebo

Alzheimer Disease Clinical Trial using Multi-sensory supportive care

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 18 years or older.
- Evaluation of the Impact of Care Based on Sensory Support for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease.
Multi-sensory supportive care

Mild-Moderate Alzheimer's Disease, or Healthy Elderly Clinical Trial using MEDI1814 for IV injection; MEDI1814 for Subcutaneous Injection; IV Placebo; Placebo for Subcutaneous Injection

AstraZeneca - Recruiting 55 years to 85 years.
- A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease..
MEDI1814 for IV injection; MEDI1814 for Subcutaneous Injection; IV Placebo; Placebo for Subcutaneous Injection

Alzheimer's Disease Clinical Trial using Placebo; Lu AE58054

H. Lundbeck A/S - Recruiting 50 years or older.
- Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil.
Placebo; Lu AE58054

Alzheimer Disease Clinical Trial using gantenerumab; placebo

Hoffmann-La Roche - Recruiting 50 years to 90 years.
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE.
gantenerumab; placebo

Alzheimer Disease Clinical Trial using JNJ-54861911 10 mg; JNJ-54861911 50 mg; Placebo

Janssen Research & Development, LLC - Recruiting 50 years to 90 years.
- A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aá Processing in CSF and Plasma.
JNJ-54861911 10 mg; JNJ-54861911 50 mg; Placebo

Amnestic Mild Cognitive Impairment, or Alzheimer's Disease Clinical Trial using Insulin (Humulinr R U-100); Placebo

Alzheimer's Disease Cooperative Study (ADCS) - Recruiting 55 years to 85 years.
- Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD).
Insulin (Humulinr R U-100); Placebo

Alzheimer's Disease Clinical Trial using BNC

National Institutes of Health Clinical Center (CC) - Recruiting 55 years or older.
- Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers.
BNC

Alzheimer's Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 20 years or older.
- Early Markers of Alzheimer's Disease in BLSA Participants: Structural and Functional Brain Changes.

Alzheimer's Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 60 years or older.
- Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology.

Alzheimer's Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 45 years or older.
- Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease.

Alzheimer's Disease Clinical Trial using Epigallocatechin-Gallate; Placebo

Charite University, Berlin, Germany - Recruiting 60 years or older.
- Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer's Disease.
Epigallocatechin-Gallate; Placebo

Alzheimer's Disease Clinical Trial using AC-1204; Placebo

Accera, Inc. - Recruiting 66 years to 90 years.
- A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension.
AC-1204; Placebo

Alzheimer Disease Clinical Trial using placebo; gantenerumab

Hoffmann-La Roche - Recruiting 50 years to 85 years.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for an Additional Two Years of Treatment.
placebo; gantenerumab

Alzheimer's Disease Clinical Trial

Shanghai Mental Health Center - Recruiting 60 years to 90 years.
- Shanghai Mental Health Center.

Alzheimer's Type Dementia Clinical Trial using E2020

Eisai Inc. - Recruiting 50 years or older.
- Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease.
E2020

Alzheimer's Disease Clinical Trial using Oxaloacetate (OAA)

University of Kansas - Recruiting 18 years or older.
- Oxaloacetate Pharmacokinetics and Safety.
Oxaloacetate (OAA)

Amnestic Mild Cognitive Impairment, Alzheimer's Disease, or Prodr Clinical Trial using MK-8931; Placebo

Merck Sharp & Dohme Corp. - Recruiting 50 years to 85 years.
- A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).
MK-8931; Placebo

Alzheimer's Disease Clinical Trial using AZD3293; Placebo; Moxifloxacin

AstraZeneca - Recruiting 18 years to 55 years.
- A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects.
AZD3293; Placebo; Moxifloxacin

Alzheimer Disease Clinical Trial using RO4602522; RO4601522; placebo; donepezil; rivastigmine; galantamine; memantine

Hoffmann-La Roche - Recruiting 50 years to 90 years.
- A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIENTS WITH MODERATE SEVERITY ALZHEIMER'S DISEASE.
RO4602522; RO4601522; placebo; donepezil; rivastigmine; galantamine; memantine

Mild Cognitive Impairment, or Mild to Moderate Cognitive Impairme Clinical Trial using spectral-domain optical coherence tomography (SD-OCT)

Duke University - Recruiting 55 years or older.
- Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease.
spectral-domain optical coherence tomography (SD-OCT)

Alzheimer's Disease Clinical Trial using Exendin-4 (Exenatide)

National Institutes of Health Clinical Center (CC) - Recruiting 60 years or older.
- A Clinical Trial of Exendin-4 for the Treatment of Alzheimer's Disease.
Exendin-4 (Exenatide)

Frontotemporal Dementia, or Alzheimer's Disease Clinical Trial

Norwegian Centre for Ageing and Health - Recruiting N/A to 69 years.
- A Nordic Multicentre Observational Study of Persons With Young Onset Dementia and Their Families - Factors Influencing Quality of Life, Theirs Specific Needs and the Use of Healthcare Resources.

Alzheimer's Disease Prevention Clinical Trial using Aerobic vs. Non-Aerobic exercise

Mayo Clinic - Recruiting 65 years or older.
- Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study/ 18F-AV-45-A14 - CLINICAL EVALUATION OF FLORBETAPIR F 18 (18F-AV-45) Sponsor of 18F-AV-45-A14: Avid Radiopharmaceuticals.
Aerobic vs. Non-Aerobic exercise

Mild Cognitive Impairment Due to Alzheimer's Disease Clinical Trial using Pioglitazone; Pioglitazone placebo

Takeda - Recruiting 65 years to 83 years.
- A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 0.8 SR mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects.
Pioglitazone; Pioglitazone placebo

Alzheimer's Disease, or Dementia Clinical Trial using Drug: EVP-6124; Placebo

EnVivo Pharmaceuticals, Inc. - Recruiting 55 years to 85 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.
Drug: EVP-6124; Placebo

Alzheimer's Disease, or Dementia Clinical Trial using Drug: EVP-6124; Placebo

EnVivo Pharmaceuticals, Inc. - Recruiting 55 years to 85 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.
Drug: EVP-6124; Placebo

Alzheimer's Disease Clinical Trial

Washington University School of Medicine - Recruiting 18 years or older.
- Dominantly Inherited Alzheimer Network (DIAN).

Alzheimer's Disease Clinical Trial using MT-4666; Placebo

Mitsubishi Tanabe Pharma Corporation - Recruiting 50 years to 85 years.
- A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease..
MT-4666; Placebo

Alzheimer's Disease Clinical Trial using MK-8931; Placebo

Merck Sharp & Dohme Corp. - Recruiting 55 years to 85 years.
- A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-07)(Also Known as SCH 900931, P07738).
MK-8931; Placebo

Alzheimer's Disease Clinical Trial using MK-7622; Placebo; Donepezil

Merck Sharp & Dohme Corp. - Recruiting 55 years to 85 years.
- A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects With Alzheimer's Disease.
MK-7622; Placebo; Donepezil

Alzheimer's Disease Clinical Trial using TPI-287 2 mg/m2; TPI-287 6.3 mg/m2; TPI-287 20 mg/m2; Placebo

University of California, San Francisco - Recruiting 50 years to 82 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease.
TPI-287 2 mg/m2; TPI-287 6.3 mg/m2; TPI-287 20 mg/m2; Placebo

Alzheimer's Disease Psychosis Clinical Trial using Pimavanserin tartrate; Placebo

ACADIA Pharmaceuticals Inc. - Recruiting 50 years or older.
- A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease.
Pimavanserin tartrate; Placebo

Alzheimer's Disease Clinical Trial using Placebo; Lu AE58054

H. Lundbeck A/S - Recruiting 50 years or older.
- Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil.
Placebo; Lu AE58054

Alzheimer's Disease Clinical Trial using Solanezumab; Placebo

Eli Lilly and Company - Recruiting 55 years to 90 years.
- Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo.
Solanezumab; Placebo

Alzheimer Disease Clinical Trial using Anatabloc(R); Placebo

Rock Creek Pharmaceuticals, Inc. - Recruiting 65 years to 90 years.
- 3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease.
Anatabloc(R); Placebo

Alzheimer's Disease, or Dementia Clinical Trial using Cholinesterase Inhibitor; Placebo

Sunnybrook Health Sciences Centre - Recruiting 55 years or older.
- A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting.
Cholinesterase Inhibitor; Placebo

Alzheimers Disease, Dementia, or Alzheimers Disease, Familial Clinical Trial using Gantenerumab; Solanezumab; Matching Placebo (Gantenerumab); Matching Placebo (Solanezumab)

Washington University School of Medicine - Recruiting 18 years to 80 years.
- A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease.
Gantenerumab; Solanezumab; Matching Placebo (Gantenerumab); Matching Placebo (Solanezumab)

Alzheimer Disease, Late Onset Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 65 years or older.
- New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study.

Alzheimer's Disease Clinical Trial using Albumin; Immune globulin

Grifols Biologicals Inc. - Recruiting 55 years to 85 years.
- A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy And Safety Of Short-Term Plasma Exchange Followed By Long-Term Plasmapheresis With Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD.
Albumin; Immune globulin

Alzheimer's Disease Clinical Trial using Coconut Oil Beverage; Placebo Beverage

University of South Florida - Recruiting 55 years to 90 years.
- A Randomized, Double-Blind, Placebo-Controlled, 6 Month Cross-Over Study to Evaluate the Efficacy of Coconut Oil (Fuel for ThoughtT) Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Coconut Oil Beverage; Placebo Beverage

Alzheimer Disease, Mild Cognitive Impairment, or Delirium, Dement Clinical Trial using Donepezil

New York State Psychiatric Institute - Recruiting 55 years to 95 years.
- Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly.
Donepezil

Alzheimer Disease Clinical Trial using questioning

Hospices Civils de Lyon - Recruiting 50 years or older.
- The Role of Personality in the Occurrence of Behavioural Disorders in Patients Suffering From Alzheimer Disease.
questioning

Agitation, or Alzheimer's Disease Clinical Trial using AVP-923 (dextromethorphan/quinidine); Placebo

Avanir Pharmaceuticals - Recruiting 50 years to 90 years.
- A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease..
AVP-923 (dextromethorphan/quinidine); Placebo

Alzheimer's Disease Clinical Trial using Florbetapir (18F)

Avid Radiopharmaceuticals - Recruiting N/A or older.
- Evaluation of Computer-Based Training to Educate Japanese Physicians in the Methods of Interpreting Florbetapir (18F) PET Scans.
Florbetapir (18F)

Alzheimer's Disease, or Dementia Clinical Trial

Banner Health - Recruiting 18 years or older.
- Alzheimer's Prevention Registry.

Alzheimer's Disease Clinical Trial using florbetapir F 18; 18F-AV-1451

Avid Radiopharmaceuticals - Recruiting 20 years or older.
- An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease.
florbetapir F 18; 18F-AV-1451

Alzheimer's Disease Clinical Trial using Nilvadipine; Placebo

St. James's Hospital, Ireland - Recruiting 50 years or older.
- A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease.
Nilvadipine; Placebo

Alzheimer's Disease Clinical Trial using Deep Brain Stimulation

Ohio State University - Recruiting 45 years to 85 years.
- Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease.
Deep Brain Stimulation

Alzheimer's Disease Clinical Trial using TMS and cognitive stimulation; sham

Neuronix Ltd - Recruiting 60 years to 90 years.
- Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients.
TMS and cognitive stimulation; sham

Mild Cognitive Impairment, Alzheimer's Disease, or Traumatic Brai Clinical Trial using explicit memory training; implicit memory training

Department of Veterans Affairs - Recruiting 18 years to 88 years.
- Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI.
explicit memory training; implicit memory training

Alzheimer's Disease Clinical Trial using [11C]PIB

Johns Hopkins University - Recruiting 18 years to 80 years.
- '[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls'.
[11C]PIB

Alzheimer's Disease, or Dementia Clinical Trial using Drug: NIC5-15; Placebo

James J. Peters Veterans Affairs Medical Center - Recruiting 40 years to 95 years.
- A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease.
Drug: NIC5-15; Placebo

Mild Cognitive Impairment (MCI), or Alzheimer's Disease Clinical Trial

Alzheimer's Disease Cooperative Study (ADCS) - Recruiting 55 years to 90 years.
- Alzheimer's Disease Neuroimaging Initiative 2.

Alzheimer's Disease Clinical Trial using rTMS real-sham; rTMS sham-real

University of Manitoba - Recruiting 50 years to 90 years.
- Investigating the Effect of Repetitive Transcranial Magnetic Stimulation as a Treatment for Alzheimer's Disease and on Sleep Quality.
rTMS real-sham; rTMS sham-real

Neurodegenerative Diseases, or Memory Disturbances Clinical Trial

Maastricht University Medical Center - Recruiting 18 years or older.
- Novel Diagnostic Approaches for the Diagnosis of Alzheimer's Disease: Technology Assessment and Clinical Effectiveness.

Alzheimer Disease, Late Onset Alzheimer Disease, or Dementia Clinical Trial

Indiana University - Recruiting N/A or older.
- Alzheimer's Disease Genetics Study.

Alzheimer's Disease Clinical Trial using Memantine

Peking University - Recruiting 50 years or older.
- The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study.
Memantine

Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairme Clinical Trial using COGNISIONT System

Neuronetrix, Inc. - Recruiting 60 years to 90 years.
- Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISIONT) as a Useful Cognitive Biomarker for Alzheimer's Disease..
COGNISIONT System

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous Syst Clinical Trial using NEUROSTEMr-AD

Samsung Medical Center - Recruiting 50 years to 75 years.
- The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostemr-AD.
NEUROSTEMr-AD

Alzheimer's Disease Clinical Trial using Thalidomide

Banner Health - Recruiting 50 years to 90 years.
- 'Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease.
Thalidomide

Alzheimer Disease, Stroke, Parkinson's Disease, Lewy Body Dementi Clinical Trial using Computerized tests and Electrophysiological measurements

Centre Hospitalier Universitaire, Amiens - Recruiting 18 years to 85 years.
- Assessment of Social-emotional Functioning in Stroke, Frontotemporal Dementia, Alzheimer and Parkinson Diseases.
Computerized tests and Electrophysiological measurements

Alzheimer's Disease, Mild Cognitive Impairment, or Age-Related Me Clinical Trial

University of Arizona - Recruiting 50 years or older.
- Arizona Alzheimer's Disease Core Center.

Alzheimer's Disease Clinical Trial using Stimulation group

Association Recherche M‚thodologie Evaluation Psychiatrique - Recruiting 60 years or older.
- Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home.
Stimulation group

Dementia of the Alzheimer Type Clinical Trial using StaCog, stage specific cognitive Intervention; booklet based training

University of Rostock - Recruiting 55 years or older.
- Effect of the Stage Specific Cognitive Intervention Program on Functional Cortical Activation in Alzheimer's Disease.
StaCog, stage specific cognitive Intervention; booklet based training

Alzheimer's Disease Clinical Trial using donepezil

Vanderbilt University - Recruiting 40 years to 85 years.
- Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease.
donepezil

Alzheimer's Disease Clinical Trial using Clinic and neuropsychologic evaluation; MRI; PET; Apolipoprotein E genotyping; Study of cerebrospinal fluid

Assistance Publique Hopitaux De Marseille - Recruiting 45 years to 90 years.
- Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) : Variations of the Clinical Profile and Paraclinical Features Depending on the Age at the Onset of Clinical Signs.
Clinic and neuropsychologic evaluation; MRI; PET; Apolipoprotein E genotyping; Study of cerebrospinal fluid

Alzheimer's Disease, Dementia, or Neurodegenerative Disorders Clinical Trial using Blood sampling, skin biopsy

Institut National de la Sant‚ Et de la Recherche M‚dicale, France - Recruiting 18 years to 90 years.
- Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment.
Blood sampling, skin biopsy

Alzheimer's Disease Clinical Trial

National Institute on Aging (NIA) - Recruiting 60 years to 90 years.
- Implications of Amyloid Deposition in Clinically Normal Older Individuals.

Down Syndrome, or Alzheimer's Disease Clinical Trial

National Institute on Aging (NIA) - Recruiting 21 years or older.
- Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome.

Falls, or Alzheimer's Disease Clinical Trial using Wii-Fit intervention; Walking

University of Nebraska - Recruiting 60 years or older.
- Wii-fit for Activity, Balance and Gait in Assisted Living.
Wii-Fit intervention; Walking

Depression Clinical Trial using Problem-solving therapy; Nutritional education program

National Institute of Mental Health (NIMH) - Recruiting 18 years or older.
- Prevention of Psychiatric Morbidity in AD Caregivers.
Problem-solving therapy; Nutritional education program